Objectives: This study compared mortality and reinterventions between patients randomized to either an endovascular strategy or open repair 3 years previously and evaluated how these outcomes were influenced by preoperative aortoiliac morphology.
Methods: Multicenter randomized controlled trial (ISRCTN 48334791), recruiting 613 patients between September 2009 and July 2013: computed tomography (CT) scans were assessed in a core laboratory. Patients were followed up by trial centers, with deaths reported by national registers and reinterventions taking place at nontrial centers obtained from audit and/or administrative databases. After patient discharge, reinterventions were categorized as arterial, laparotomyrelated, or other and scored for clinical severity by investigator consensus and patient-perceived severity. The influence of preoperative aortoiliac morphology on reinterventions was assessed. Statistical analysis was according to prespecified plans approved by the trial writing committee (Table) .
Results: After 3 years, five patients had been lost to follow-up due to emigration, and 151 of 313 (48%) and 165 of 295 (56%) patients had died in the endovascular strategy and open repair groups, respectively (c 2 P ¼ .058). There was a similar quality-adjusted life-year benefit for the endovascular strategy group at 3 years. In the endovascular strategy group, there were 130 reinterventions in 76 of 316 patients. In the open repair group, there were 113 reinterventions in 68 of 297 patients. Over the 3 years of follow-up, the rate at which reinterventions occurred were similar in the 2 groups (24.0 and 26.8 per 100 person-years in the endovascular strategy and open repair groups, respectively). Between 3 months and 3 years the reintervention rate was low but twice as high in the endovascular strategy group (8.4 vs 4.3 per 100 personyears), although many of these reinterventions were minor (severity score to be presented). From a patient perspective, there were more severe reinterventions (limb amputation, graft infection, secondary ruptures, major redo procedures, and unclosed ostomies) in patients following open repair (19 of 248 vs 7 of 186; c 2 P ¼ .09). There were three secondary ruptures within 3 years of follow-up, all in EVAR patients. The influence of preoperative aortoiliac morphology on reintervention rates also will be reported.
Conclusions: After 3 years, the endovascular strategy emerges as the better care pathway for patients and does not appear to be associated with a greater rate of serious late reinterventions. Future reporting standards for ruptured aneurysm repair should include metrics such as amputation and graft infection (important to patients).
Author Disclosures: I. Investigators: Nothing to disclose; J. T. Powell: Nothing to disclose.
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A Objectives: Fenestrated endografts are customized, patient-specific, endovascular devices with the potential to reduce morbidity and mortality of repair of complex aortic aneurysms. With approval from the United States Food and Drug Administration, our center began performing fenestrated endovascular aneurysm repair through a physician-sponsored investigational device exemption (IDE #G130210), using both physician-modified endografts (PMEG) and company manufactured devices (CMD). Because PMEG and CMD are each associated with specific advantages and disadvantages, we sought to investigate differences in outcomes between PMEG and CMD cases.
Methods: A single-institution retrospective review of all fenestrated endovascular aneurysm repairs was performed. The cohort was analyzed according to device type (PMEG or CMD) after matching cases based on (1) number of target vessels intended for treatment, (2) extent of aneurysm, (3) aneurysm diameter, (4) device configuration, and (5) date of operation. Outcomes of ruptures, common iliac, and arch aneurysms were excluded. Demographics, operative details, perioperative complications, length of stay, and reinterventions were compared. For patients (PMEG, 6; CMD, 8) , and 30 thoracoabdominal types 1 to 4 (PMEG, 18; CMD, 12) aneurysms. There were significant differences in urgency of presentation (PMEG, 9; CMD, 0; P ¼ .002), total fluoroscopy time (PMEG, 76 minutes; CMD, 61 minutes; P ¼ .02), volume of contrast used (PMEG, 88 mL; CMD, 70 mL; P ¼ .02), in-operating room to out-of-operating room time (PMEG, 391 minutes; CMD, 319 minutes; P ¼ .001), incision-to-surgery-end time (PMEG, 276 minutes; CMD, 224 minutes; P ¼ .002; Table) , and 1-year reintervention rate (PMEG, 37%, CMD, 13%; logrank P ¼ .04; Fig) . No differences in perioperative complications, overall length of stay, type I or III endoleak, or survival were observed between PMEG vs CMD.
Conclusions: In this single-institution experience of fenestrated endovascular aneurysm repair, the primary differences between PMEG and CMD related only to operative technique and postoperative reinterventions. No clear benefit was associated with one approach over the other, suggesting that both are viable options that may offer benefit compared with open repair of complex aortic aneurysms. Further studies are necessary to determine if this relative equivalence represents a type 2 error and/or lack of long-term durability data or if true equivalence between PMEG and CMD approaches exists. For patients who underwent a staged procedure with PMEG (n ¼ 3) or CMD (n ¼ 2), operating room direct cost included total operating room costs for both stages of the repair. Costs attributed to operating room usage time were not included in the total cost calculation.
VS01. Neoaortoiliac System (NAIS) Procedure for Infected Aortobifemoral Graft
Caitlin W. Hicks, James H. Black III. Johns Hopkins Hospital, Baltimore, Md
Background: The neoaortic system (NAIS) procedure has been previously described for the treatment of infected aortic grafts, but the technical details of execution are elusive to the majority of vascular surgeons. In this video, we demonstrate the key steps involved in performing a successful NAIS.
http://www.conferenceabstracts.com/uploads/cfp2/attachments/ZRFDQ HCR/ZRFDQHCR-291895-1-ANY.mov Author Disclosures: J. H. Black: Nothing to disclose; C. W. Hicks: Nothing to disclose. Objectives: Crescendo transient ischemic attack (cTIA) in symptomatic carotid artery stenosis is a rare condition requiring a prompt intervention to reduce the stroke risk. Few data are reported in literature about cTIA and suggest a different perioperative risk compared with patients with single TIA (sTIA). This study aimed to compare the perioperative outcome of carotid endarterectomy (CEA) in patients with cTIA and sTIA and to evaluate the relative predictors of outcome.
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Open Extraction of an Infected Aortic Endograft
Methods: Data from the two tertiary hospitals for vascular treatment, serving a metropolitan area of 1 million people, were analyzed from 2007 to 2016. All patients with TIA who underwent CEA were considered, comparing the 30-day postoperative stroke and stroke/death in patients with cTIA and sTIA, particularly in the urgent (#48 hours) setting. Risk factors for perioperative stroke and death were evaluated by univariate and multivariate analysis.
Results: In a 10-year period, 3866 CEAs were performed. Of the 888 (23%) CEAs in symptomatic patients, 515 (58%) were performed in patients with sTIA and 150 (17%) in cTIA. Patients with amaurosis fugax (25 [3%]) or stroke (198 [25%] ) were excluded from the analysis. cTIA patients were less frequently affected by coronary artery disease, dyslipidemia, and chronic obstructive pulmonary disease, and were younger, but more frequently were affected with contralateral carotid occlusion, compared with patients with sTIA (20% vs 10%, P ¼ .004; 56% vs 46, P ¼ .03; 16% vs 7%, P ¼ .01; >80 years 26% vs 16%, P ¼ .01 and 2% vs 10%, P ¼ .001, respectively). Postoperative stroke and stroke/death were significantly higher in cTIA compared with sTIA (5.5% vs 1.6% [P ¼ .02] and 6.0% vs 2.2% [P ¼ .03], respectively). Urgent CEA was performed in 58% (n ¼ 87) of cTIA and in 11% (n ¼ 56) of sTIA (P < .01). The urgent setting did not influence the stroke and stroke/death rate of CEA for sTIA (3.6% vs 1.3% [P ¼ .21 ] and 3.6% vs 1.9% [P ¼ .44] , respectively), but was associated with lower rate of events in patients with cTIA (1.1% vs 11.1% [P ¼ .01 ] and 2.3% vs 11.1% [P ¼ .03] , respectively). This beneficial effect in patients with cTIA treated within 48 hours was confirmed also by multivariate analysis (odds ratio, 0.09; 95% confidence interval, 0.76-0.01; P ¼ .02).
Conclusions: Patients with cTIA who undergo CEA have a higher stroke and stroke/death risk compared with patients with sTIA, possibly associated with the unstable neurologic status of cTIA. In this context, urgent CEA of cTIA can significantly reduce the complication rate, as shown by our results. In patients with sTIA with a stable neurologic condition, the timing of CEA did not influence the outcome.
Author Disclosures: L. Cacioppa: Nothing to disclose; G. Faggioli: Nothing to disclose; E. Gallitto: Nothing to disclose; M. Gargiulo: Nothing to disclose; A. Pilato: Nothing to disclose; R. Pini: Nothing to disclose; E. Pisano: Nothing to disclose; A. Stella: Nothing to disclose. Methods: From January 2005 to December 2015, 147 consecutive elective interventions for post-CEA restenosis were performed in our institution. A retrospective analysis of clinical records was performed, and 80 interventions carried out with carotid artery stenting (CAS) were found, while the remaining 67 interventions were open. Propensity score-based matching was performed to adjust for confounding factors in a 1:1 ratio to compare outcomes. Covariates included coronary artery disease, degree of the carotid restenosis, timing of the reintervention with respect to the primary intervention (higher or lower than 24 months), and the presence of ipsilateral brain lesions at the preoperative computed tomography scan. Perioperative outcomes were analyzed with the c 2 test, and late results were estimated by Kaplan-Meier methods.
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Results: After propensity matching, 32 CAS interventions (group 1) were matched with 32 redo CEAs (group 2). There were no perioperative deaths or strokes; two patients in group 2 experienced a perioperative transient ischemic attack and an acute myocardial infarction, respectively. Cranial nerve palsy occurred in seven patients in group 2; in six of them, complete regression was found at a 1-month follow-up otolaryngologist visit. All patients had an available follow-up, with a mean duration of 41 months (range, 6-120 months); the mean follow-up index was 0.72 (range, 0.1-1). Estimated 4-year survival rates were 93% (standard error [SE] , 0.06%) in group 1 and 88.5% (SE, 0.06%) in group 2 (P ¼ .1; log-rank, 2.6). There were no differences between the two groups in stroke-free survival and any neurologic symptom-free survival. In group 1, no severe (>70%) restenoses were found, while in group 2, eight patients had severe restenosis or occlusion of the operated carotid artery. Freedom from secondary restenosis at 4 years was 100% in group 1 and 71.5% in group 2 (SE, 0.08%; P ¼ .004, log-rank, 8.2). The corresponding figures in freedom from secondary reintervention were 100% and 83% (SE, 0.07%; P ¼ .02, log-rank, 5).
Conclusions: CAS and redo CEA in patients with post-CEA restenosis provided in this retrospective single-center experience similar
